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Abstract 
Background: Malariometric information is needed to decide how to introduce malaria vaccines and evaluate their 
impact in sub‑Saharan African countries.
Methods: This cross‑sectional study (NCT01954264) was conducted between October and November, 2013, cor‑
responding to the high malaria transmission season, in four sites with Health and Demographic Surveillance Systems 
(DSS) [two sites with moderate‑to‑high malaria endemicity in Burkina Faso (Nouna and Saponé) and two sites with 
low malaria endemicity in Senegal (Keur Socé and Niakhar)]. Children (N = 2421) were randomly selected from the 
DSS lists of the study sites and were stratified into two age groups (6 months–4 years and 5–9 years). A blood sam‑
ple was collected from each child to evaluate parasite prevalence of Plasmodium falciparum and other Plasmodium 
species and gametocyte density by microscopy, and rapid diagnosis test in the event of fever within 24 h. Case report 
forms were used to evaluate malaria control measures and other factors.
Results: Plasmodium falciparum was identified in 707 (29.2%) children, with a higher prevalence in Burkina Faso 
than Senegal (57.5 vs 0.9% of children). In Burkina Faso, prevalence was 57.7% in Nouna and 41.9% in Saponé in the 
6 months–4 years age group, and 75.4% in Nouna and 70.1% in Saponé in the 5–9 years age group. Infections with 
other Plasmodium species were rare and only detected in Burkina Faso. While mosquito nets were used by 88.6–97.0 
and 64.7–80.2% of children in Burkina Faso and Senegal, other malaria control measures evaluated at individual level 
were uncommon. In Burkina Faso, exploratory analyses suggested that use of malaria treatment or any other medica‑
tion within 14 days, and use of insecticide spray within 7 days decreased the prevalence of malaria infection; older 
age, rural residence, natural floor, grass/palm roof, and unavailability of electricity in the house were factors associated 
with increased malaria occurrence.
Conclusions: Plasmodium falciparum infection prevalence in children younger than 10 years was 57.5% in Bur‑
kina Faso and 0.9% in Senegal, and variability was observed, among others, by age, study site and malaria control 
measures.
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Background
In sub-Saharan Africa, malaria remains a major cause of 
morbidity and mortality, especially in young children [1]. 
In 2013, when the current study was conducted, approxi-
mately 198 million malaria cases occurred globally, caus-
ing 584,000 deaths. Most cases (90%) occurred in Africa, 
and most deaths (78%) were in children under 5 years of 
age [2].
In many African countries, malaria control pro-
grammes have been implemented since 2000, including 
the use of insecticide-treated nets (ITNs), long-lasting 
insecticidal nets (LLINs), indoor residual spraying of 
insecticides (IRS), rapid diagnostic tests (RDTs), and 
effective anti-malaria medicines [1]. Although these 
interventions have been associated with a reduction in 
malaria incidence rates, the increasing problem of multi-
drug resistance and insecticide resistance highlights the 
need for new tools, especially in areas of moderate-to-
high malaria transmission intensity (MTI) [1, 3–7].
Adding a malaria vaccine to the control programmes 
has been identified as a key component to complement 
current interventions [8, 9]. RTS,S/AS01 is the first 
malaria vaccine that underwent large-scale phase 3 eval-
uation in Africa [4, 10–12] and received a positive regu-
latory assessment by the European Medicines Agency 
in July 2015 [13]. Before considering its introduction 
for routine use, the World Health Organization (WHO) 
recommended further evaluation of its four-dose vac-
cination schedule in a series of pilot implementations in 
moderate-to-high transmission settings in sub-Saharan 
Africa [1].
Malariometric information is needed to guide deci-
sions on how to prioritize interventions and introduce 
malaria vaccines. Among others, the level of malaria 
transmission, which is very heterogeneous within geo-
graphical areas, may have an effect on the efficacy of 
malaria control measures, including RTS,S/AS01 [12, 14]. 
The objectives of the present study were to evaluate the 
parasite prevalence (PP): an indirect, cost-effective way 
to evaluate the force of malaria transmission) of Plas-
modium falciparum and other Plasmodium species, the 
extent of use of malaria control measures, and other fac-
tors in four sites, where phase IV studies on RTS,S/AS01 
were expected to be conducted. These results are needed 
to anticipate the impact of RTS,S/AS01 if this vaccine is 




This epidemiological, cross-sectional study was carried 
out at four sites with Health and Demographic Surveil-
lance Systems (HDSS) in Burkina Faso and Senegal 
(NCT01954264). The first site was located in the area 
of Nouna at about 300  km from Ouagadougou (north-
western Burkina Faso), where malaria is hyper- to holo-
endemic, the malaria transmission peak occurs at the 
end of the rainy season (June to October), and reduced 
transmission is observed during the dry season (Decem-
ber to May) [15]. The second site in Burkina Faso was 
located in Saponé (30  km southwest of Ouagadougou), 
where malaria transmission is also seasonal, and the peak 
is observed at the end of the rainy season in September 
[16]. The third site was located in the Keur Socé area 
(200 km southeast of Dakar, Senegal), which is character-
ized by the alternation of a long dry season and a short 
rainy season from July to November, and has a peak in 
malaria transmission between October and November 
[17, 18]. The last site was located in the Niakhar area 
(115  km southeast of Dakar, Senegal), where malaria is 
meso-endemic and transmission is seasonal from Sep-
tember to December [19].
Study population
Participants were children aged ≥6 months to <10 years, 
whose parents or legally acceptable representative had 
provided informed consent prior to any study-specific 
procedure. Children in care, or actively participating in 
any trial involving administration of an investigational 
malaria vaccine or drug were excluded. Children were 
randomly selected from the HDSS list at each site, and 
were stratified into two age groups for the analyses, as 
defined by the Joint Technical Expert Group (JTEG) 
criteria: children aged 6 months–4 years and children 
aged 5–9 years. Analyses were performed on all evalu-
able children for whom at least one laboratory result was 
available.
Data collection
This study was conducted during or just after the rainy 
season, at the peak of malaria transmission. Data were col-
lected at one visit between 19 October and 25 November, 
2013, and no follow-up was done (Fig. 1). Internet-based 
electronic case report forms were used to record demo-
graphic details, relevant medical history, malaria control 
Keywords: Malaria, Burkina Faso, Senegal, Epidemiological study, Parasite prevalence, Risk factors,  
Preventive interventions
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measures used in the household, malaria risk factors, anti-
malaria medication and other medication received within 
14 days, and history of fever in the last 24 h. Axillary body 
temperature at the time of the survey was measured by 
trained personnel according to the study protocol.
The malaria control measures evaluated at the individual 
level were the use of mosquito bed nets the night before the 
visit, mosquito coils, insecticide sprays, and commercial 
and traditional repellents over 7 days, and IRS on interior 
walls in previous 12 months. The other factors evaluated in 
this study were age, gender, study centre, number of per-
sons living in the same house, localization (rural vs urban 
area; town vs countryside), main house construction mate-
rial (walls, floor, roof, windows/eaves, nets), main source of 
drinking water, and availability of electricity.
Each study site was requested to provide centre-specific 
information about control measures from the malaria 
control programme in the study area and, if available, 
meteorological data for the study site, such as rainfall and 
temperature. The information was collected in the form 
of a questionnaire recorded in a separate database.
Biological methods
Approximately 200 µL of whole blood was collected from 
all participants. A RDT was performed in the event of 
recent history of fever (axillary temperature  ≥37.5  °C 
measured at the time of visit or reported in the previous 
24  h). The RDT was used to detect HRP-II (Histidine-
rich protein II) specific to P. falciparum and pLDH (Plas-
modium lactate dehydrogenase) specific to Plasmodium 
vivax (SD BIOLINE Malaria Ag P.f/P.v test). If the RDT 
was positive or the child was identified as being para-
site-positive following microscopy, treatment was given 
according to national guidelines.
The presence of parasites on capillary blood samples 
was assessed by 100-field microscopic examination, 
assuming 8000 leukocytes/µl of blood. The count was 
made by species (P. falciparum, P. malariae, P. vivax, or 
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Fig. 1 Plasmodium falciparum parasite prevalence, annual rainfall and enrolment period for the study center of a Nouna (Burkina Faso), b Saponé 
(Burkina Faso), c Niakhar (Senegal), and d Keur Socé (Senegal). PP parasite prevalence, M months, Y years
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Plasmodium ovale), and counts for P. falciparum were 
made for both gametocytes and asexual parasites. Two 
slides, each containing a thick and thin blood smear, 
were prepared; positive parasitaemia was identified on 
the thick blood film, and species on the thin blood film, 
except in case of low parasitaemia. The parasite presence 
and density were determined independently by two read-
ers for the same slide; if readings were judged to be dis-
cordant, a third independent read was organised. A child 
was defined as infected by a specific parasite if at least 
two readings were positive for the corresponding para-
site. If the final decision was positive, the parasite den-
sity (parasites/μL) was calculated as the geometric mean 
of the two positive readings (two geometrically closest 
readings in the case of three positive reads). The follow-
ing classes were used to categorize the parasite densities: 
low (<2500 parasites/μL); medium (2500–9999 parasites/
μL); high (10,000–19,999 parasites/μL), and very high 
(≥20,000 parasites/μL).
A child was defined as having gametocytes when 
gametocytes were detected during at least one reading. 
In children with a positive status, the gametocyte den-
sity (units/μL) was defined as the geometric mean of the 
readings of the positive slides.
Statistical methods
The target sample size was 2400 children (600 at each 
participating site), according to the following stratifica-
tion by age groups: 6  months-<1 year-olds (N  =  60), 1 
and 2 year-olds (N =  120 per group), 3 and 4 year-olds 
(N = 50 per group), and 5, 6, 7, 8, and 9 year-olds (N = 40 
per group). To allow for 10% non-response, 660 children 
over all age categories were randomly selected from 
the demographic surveillance system databases of each 
site. This sample size ensured sufficiently narrow confi-
dence intervals (CIs) around centre-wise PP estimates 
(with a maximum relative standard error of 0.25) in chil-
dren from the 6 months–4 years (JTEG definition) and 
29 years (WHO definition) age groups for sites with low 
(<10%), moderate (10–50%), or high (>50%) endemicity.
Continuous variables were described with mean, stand-
ard deviation (SD), median, and range. Categorical vari-
ables were described in frequency tables with absolute 
numbers and percentages. For some categorical vari-
ables, 95% CIs were also calculated.
Potential differences between groups were detected 
in exploratory analyses based on non-overlapping 95% 
CIs. The impact of various malaria control measures 
and other factors on the P. falciparum infection status 
was evaluated as exploratory analysis by centre in uni-
variate logistic regression analyses and summarized using 
unadjusted odds ratios (ORs) with 95% CIs. A potential 
impact was detected if the 95% CI of the unadjusted ORs 
did not include the value ‘1’. The statistical analyses were 
performed using the Statistical Analysis Systems, version 
9.2.
Results
Characteristics of the study participants
In this study, 2421 children were enrolled, with a simi-
lar distribution among the four sites. A few minor pro-
tocol deviations were reported (inconsistencies in terms 
of RDT testing based on the temperature), but no child 
was excluded from the total cohort randomly selected 
to participate in the study. A total of 1210 children 
were enrolled in Burkina Faso (610 in Nouna and 600 
in Saponé) and 1211 children in Senegal (603 in Keur 
Socé centre and 608 in Niakhar). Among all partici-
pants, 52.3% were boys, with an even gender distribution 
among the four centres. The proportion of children living 
in rural areas was higher in the two Senegalese centres 
(≥99.8%) and in Saponé (≥98.7%) than in Nouna (53.6% 
in the 6 months–4 years and 51.7% in the 5–9 years age 
groups) (Table 1).
Fever in the last 24 h was reported in 24.6, 17.5, 12.0, 
and 9.0% of children aged 6 months–4 years, and in 16.3, 
6.0, 9.8, and 5.5% of children aged 5–9 years in Nouna, 
Saponé, Keur Socé, and Niakhar, respectively (Table  1). 
The fever started, on average, 3 days before the study 
visit. At the study visit, 7.6, 8.3, 2.3, and 13.9% of chil-
dren aged 6 months–4 years and 6.9, 2.0, 2.0, and 13.6% 
of children aged 5–9 years had fever in Nouna, Saponé, 
Keur Socé, and Niakhar, respectively. Among children 
with fever, the mean (SD) temperature was 38.0 °C (0.6), 
38.1  °C (0.7), 38.4  °C (0.8), and 37.9  °C (0.5) in Nouna, 
Saponé, Keur Socé, and Niakhar, respectively.
In the Senegalese centres, ≤1.2% of children received 
any malaria treatment in the past 14 days, while in Bur-
kina Faso, this percentage was 22.1 and 16.7% in Nouna, 
and 11.0 and 5.0 in Saponé in the 6 months–4 years and 
5–9 years age groups, respectively (Table  1). The aver-
age duration of malaria treatment was 3 days, and for 
14.1% of these children, the malaria treatment was still 
ongoing at the visit. In Burkina Faso, 149 out of the 178 
children who received an anti-malarial were treated 
with artesunate-amodiaquine (83.7%), while in Sen-
egal, four/nine children were treated with dihydroarte-
misinin-piperaquine (Niakhar centre), four/nine with 
artemether-lumefantrine, and one/nine with an unknown 
medication. The proportion of children who had received 
other medications in the past 14 days ranged from 3.9 to 
43.5% (Table 1).
Parasite prevalence
Malaria infections caused by P. falciparum were detected 
in 29.2% of children; 57.9% of them were in the 6 
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Table 1 Baseline characteristics of the study participants
Site Age classes Characteristic Values
Nouna (Burkina Faso) Overall N 610
Age, mean years (SD) 4.04 (2.75)
Male, n (%) 315 (51.6%)
Female, n (%) 295 (48.4%)
6 months–4 years N 407
Rural area, n (% [95% CI]) 218 (53.6% [48.6, 58.5])
Fever in the last 24 h, n (% [95% CI]) 100 (24.6% [20.5, 29.1])
Malaria treatment in past 14 days, n (% [95% CI]) 90 (22.1% [18.2, 26.5])
Other medications in past 14 days, n (% [95% CI]) 177 (43.5% [38.6, 48.5])
5–9 years N 203
Rural area, n (% [95% CI]) 105 (51.7% [44.6, 58.8])
Fever in the last 24 h, n (% [95% CI]) 33 (16.3% [11.5, 22.1])
Malaria treatment in past 14 days, n (% [95% CI]) 34 (16.7% [11.9, 22.6])
Other medications in past 14 days, n (% [95% CI]) 66 (32.5% [26.1, 39.4])
Saponé (Burkina Faso) Overall N 600
Age, mean years (SD) 4.01 (2.74)
Male, n (%) 315 (52.5%)
Female, n (%) 285 (47.5%)
6 months–4 years N 399
Rural area, n (% [95% CI]) 394 (98.7% [97.1, 99.6])
Fever in the last 24 h, n (% [95% CI]) 70 (17.5% [13.9, 21.6])
Malaria treatment in past 14 days, n (% [95% CI]) 44 (11.0% [8.1, 14.5])
Other medications in past 14 days, n (% [95% CI]) 56 (14.0% [10.8, 17.8])
5–9 years N 201
Rural area, n (% [95% CI]) 200 (99.5% [97.3, 100])
Fever in the last 24 h, n (% [95% CI]) 12 (6.0% [3.1, 10.2])
Malaria treatment in past 14 days, n (% [95% CI]) 10 (5.0% [2.4, 9.0])
Other medications in past 14 days, n (% [95% CI]) 12 (6.0% [3.1, 10.2])
Keur Socé (Senegal) Overall N 603
Age, mean years (SD) 4.12 (2.70)
Male, n (%) 321 (53.2%)
Female, n (%) 282 (46.8%)
6 months–4 years N 399
Rural area, n (% [95% CI]) 399 (100% [99.1, 100])
Fever in the last 24 h, n (% [95% CI]) 48 (12.0% [9.0, 15.6])
Malaria treatment in past 14 days, n (% [95% CI]) 1 (0.3% [0.0, 1.4])
Other medications in past 14 days, n (% [95% CI]) 31 (7.8% [5.3, 10.8])
5–9 years N 204
Rural area, n (% [95% CI]) 204 (100% [98.2, 100])
Fever in the last 24 h, n (% [95% CI]) 20 (9.8% [6.1, 14.7])
Malaria treatment in past 14 days, n (% [95% CI]) 1 (0.5% [0.0, 2.7])
Other medications in past 14 days, n (% [95% CI]) 8 (3.9% [1.7, 7.6])
Niakhar (Senegal) Overall N 608
Age, mean years (SD) 3.98 (2.76)
Male, n (%) 315 (51.8%)
Female, n (%) 293 (48.2%)
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months–4 years age group and 42.1% in the 5–9 years 
age group (Table 2; Fig. 1). The vast majority of infections 
(98.4%) were observed in Burkina Faso. In Nouna and 
Saponé, 57.7 and 41.9% of children in the 6 months–4 
years age group, and 75.4 and 70.1% of children in the 
5–9 years age group were infected, respectively. In Keur 
Socé, 0.5% of children were infected in both age groups, 
while infections were observed in 1.2% of children in the 
6 months–4 years age group and 1.5% of children in the 
5–9 years age group in Niakhar. In Burkina Faso, the P. 
falciparum PP seemed to increase with age during the 
first 9 years of life, while it seemed more uniform in Sene-
gal (Fig. 2). Among the 404 children with results available 
for both RDT and microscopy, the degree of agreement 
between the two diagnostic tests was 85.3%.
In Burkina Faso, the minimum parasite den-
sity recorded was 16 parasites/µL in children aged 6 
months–4 years and 11.31 parasites/µL in children aged 
5–9 years. In Niakhar, similar results were obtained, 
with a minimum parasite density of 28.67 parasites/µL 
in children aged 6 months–4 years and 7.75 parasites/
µL in children aged 5–9 years. In Keur Socé, however, 
the minimum parasite density recorded in the three 
children positive for P. falciparum was higher: 244.75 
parasites/µL in the two children aged 6 months–4 years 
and 61,744.63 parasites/µL in the children aged 5–9 
years.
In Nouna, potential differences in the proportion of 
children who received any malaria treatment in the past 
14 days were detected between infected and non-infected 
children: 15.3 vs 31.4% for 6 months–4 years old chil-
dren, and 10.5 vs 36.0% for 5–9 years old children. In 6 
months–4 years old children in Saponé, potential differ-
ences were detected in terms of proportion of children 
who received any malaria treatment in the past 14 days 
(4.2% of infected children vs 15.9% of non-infected) and 
in terms of children with fever within the last 24 h (25.7% 
of infected children vs 11.6% of non-infected). In 5–9 
years old children in Saponé, 0.7 and 15.0% of infected 
and non-infected children received any malaria treat-
ment in the past 14 days, and 2.1 and 15.0% of infected 
and non-infected children received other medication in 
the past 14 days, respectively.
There was a greater likelihood of fever in the last 24 h 
for children with very high malaria parasite density 
(48.4%) compared to low (15.8%) or negative (10.8%) 
parasite density. Moreover, the overall proportion of chil-
dren hospitalized for malaria in the last 3 months tended 
to be higher in children with very high malaria parasite 
density (6.5%) compared to those with low (3.4%) or neg-
ative parasite results (1.8%).
N total number of participants, SD standard deviation, n (%) number (percentage) of participants in a given category, M months, Y years, 95% CI 95% confidence 
interval
Table 1 continued
Site Age classes Characteristic Values
6 months–4 years N 409
Rural area, n (% [95% CI]) 408 (99.8% [98.6, 100])
Fever in the last 24 h, n (% [95% CI]) 37 (9.0% [6.4, 12.3])
Malaria treatment in past 14 days, n (% [95% CI]) 5 (1.2% [0.4, 2.8])
Other medications in past 14 days, n (% [95% CI]) 56 (13.7% [10.5, 17.4])
5–9 years N 199
Rural area, n (% [95% CI]) 199 (100% [98.2, 100])
Fever in the last 24 h, n (% [95% CI]) 11 (5.5% [2.8, 9.7])
Malaria treatment in past 14 days, n (% [95% CI]) 2 (1.0% [0.1, 3.6])
Other medications in past 14 days, n (% [95% CI]) 13 (6.5% [3.5, 10.9])
Table 2 Plasmodium falciparum parasite prevalence 
by site and age group
N number of children with known results for P. falciparum parasitaemia test, n 
number of children infected by P. falciparum, PP parasite prevalence, 95% CI 95% 
confidence interval, M months, Y years
Age group Site N n PP (95% CI)
6 months–4 years Nouna (Burkina Faso) 407 235 57.74 (52.78, 62.59)
Saponé (Burkina Faso) 399 167 41.85 (36.97, 46.87)
Keur Socé (Senegal) 399 2 0.50 (0.06, 1.80)
Niakhar (Senegal) 409 5 1.22 (0.40, 2.83)
5–9 years Nouna (Burkina Faso) 203 153 75.37 (68.85, 81.13)
Saponé (Burkina Faso) 201 141 70.15 (63.31, 76.38)
Keur Socé (Senegal) 204 1 0.49 (0.01, 2.70)
Niakhar (Senegal) 199 3 1.51 (0.31, 4.34)
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Gametocytes were more frequently detected in chil-
dren from the centres with a higher PP (12.3 and 11.8% in 
Nouna, and 18.5 and 15.9% in Saponé in the 6 months–4 
years and 5–9 years age groups, respectively). In the 
Senegalese centres, the number of gametocytes was 
extremely low, with a proportion of 0.3 and 0.0% in Keur 
Socé, and 1.0 and 0.5% in Niakhar in the same age groups. 
However, gametocytes were also frequently detected in 
children with low parasite density: 39.5% of 6 months–4 
years old children and 64.9% of 5 to 9 years old children 
with gametocytes had a parasite density <2500 parasites/
µL. P. falciparum was identified in 80.6 and 86.0% of chil-
dren with gametocytes in the 6 months–4 years and 5–9 
years age groups, respectively.
No other Plasmodium species were identified in the 
Senegalese centres. In Burkina Faso, infection with P. 
malariae was observed in eight/407 (2.0%) and 12/203 
(5.9%) children in Nouna, and 15/399 (3.8%) and 20/201 
(10.0%) children in Saponé in the 6 months–4 years and 
5–9 years age groups, respectively. Infection with P. ovale 
was observed in nine children. No infection with P. vivax 
was recorded.
Impact of malaria control measures and other factors
The actual implementation of recommended malaria 
control measures was evaluated at the site level. ITNs 
were distributed for free in Niakhar, but were not free of 
charge in Nouna. No policy regarding the distribution of 
ITNs was implemented in Saponé, and no information 
was reported for Keur Socé. LLINs were distributed for 
free to pregnant women in Nouna, to the entire popula-
tion with a replacement period of ≥24 months in Saponé 
and Keur Socé, and to children younger than 5 years and 
pregnant women in Niakhar. Artemisinin-based combi-
nation therapy (ACT) was given for free to patients with 
malaria symptoms and positive RDT test at the four sites, 
except in Saponé where ACT was not free of charge.
Among the malaria control measures evaluated at the 
individual level, mosquito nets were the most frequently 
used in both countries (Table 3). In Burkina Faso, 88.6–
97.0% of children slept under a mosquito net the night 
before the visit: the vast majority were new (≥95.5% less 
than 1 year) and impregnated (≥98.5%), and less than 5% 
were pierced/torn, as reported to the investigators. In 




















































































































































































Classes of age - Site
Observed value (with 95% of CI)
Fig. 2 Plasmodium falciparum parasite prevalence by site according to age. 95% CI 95% confidence interval
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Table 3 Malaria control measures by site, age group and Plasmodium falciparum infection status
Infected children children infected with P. falciparum parasitaemia, Non-infected children children not infected with P. falciparum parasitaemia, N total number of 
participants, n number of children in a given category, % percentage of children in a given category, 95% CI 95% confidence interval, M months, Y years





N % (95% CI) N % (95% CI) N % (95% CI)
Nouna (Burkina Faso) 6 months–4 years Mosquito net in the night before visit 220 93.6 (89.7, 96.4) 169 98.3 (95.0, 99.6) 389 95.6 (93.1, 97.4)
Mosquito coils over 7 days 17 7.2 (4.3, 11.3) 11 6.4 (3.2, 11.2) 28 6.9 (4.6, 9.8)
Insecticide sprays over 7 days 7 3.0 (1.2, 6.0) 14 8.1 (4.5, 13.3) 21 5.2 (3.2, 7.8)
Commercial repellents over 7 days 1 0.4 (0.0, 2.3) 1 0.6 (0.0, 3.2) 2 0.5 (0.1, 1.8)
Residual spray on interior walls in past 
12 months
1 0.4 (0.0, 2.3) 0 0.0 (0.0, 2.1) 1 0.2 (0.0, 1.4)
5–9 years Mosquito net in the night before visit 149 97.4 (93.4, 99.3) 48 96.0 (86.3, 99.5) 197 97.0 (93.7, 98.9)
Mosquito coils over 7 days 17 11.1 (6.6, 17.2) 6 12.0 (4.5, 24.3) 23 11.3 (7.3, 16.5)
Insecticide sprays over 7 days 8 5.2 (2.3, 10.0) 4 8.0 (2.2, 19.2) 12 5.9 (3.1, 10.1)
Commercial repellents over 7 days 2 1.3 (0.2, 4.6) 1 2.0 (0.1, 10.6) 3 1.5 (0.3, 4.3)
Saponé (Burkina Faso) 6 months–4 years Mosquito net in the night before visit 161 96.4 (92.3, 98.7) 219 94.4 (90.6, 97.0) 380 95.2 (92.7, 97.1)
Mosquito coils over 7 days 2 1.2 (0.1, 4.3) 1 0.4 (0.0, 2.4) 3 0.8 (0.2, 2.2)
Commercial repellents over 7 days 1 0.6 (0.0, 3.3) 0 0.0 (0.0, 1.6) 1 0.3 (0.0, 1.4)
Residual spray on interior walls in past 
12 months
0 0.0 (0.0, 2.2) 2 0.9 (0.1, 3.1) 2 0.5 (0.1, 1.8)
5–9 years Mosquito net in the night before visit 125 88.7 (82.2, 93.4) 53 88.3 (77.4, 95.2) 178 88.6 (83.3, 92.6)
Mosquito coils over 7 days 2 1.4 (0.2, 5.0) 0 0.0 (0.0, 6.0) 2 1.0 (0.1, 3.5)
Residual spray on interior walls in past 
12 months
2 1.4 (0.2, 5.0) 0 0.0 (0.0, 6.0) 2 1.0 (0.1, 3.5)
Keur Socé (Senegal) 6 months–4 years Mosquito net in the night before visit 2 100 (15.8, 100) 275 69.3 (64.5, 73.8) 277 69.4 (64.6, 73.9)
Mosquito coils over 7 days 0 0.0 (0.0, 84.2) 33 8.3 (5.8, 11.5) 33 8.3 (5.8, 11.4)
Insecticide sprays over 7 days 0 0.0 (0.0, 84.2) 26 6.5 (4.3, 9.4) 26 6.5 (4.3, 9.4)
Traditional repellents over 7 days 0 0.0 (0.0, 84.2) 31 7.8 (5.4, 10.9) 31 7.8 (5.3, 10.8)
Residual spray on interior walls in past 
12 months
0 0.0 (0.0, 84.2) 12 3.0 (1.6, 5.2) 12 3.0 (1.6, 5.2)
5–9 years Mosquito net in the night before visit 0 0.0 (0.0, 97.5) 132 65.0 (58.0, 71.6) 132 64.7 (57.7, 71.3)
Mosquito coils over 7 days 1 100 (2.5, 100) 18 8.9 (5.3, 13.7) 19 9.3 (5.7, 14.2)
Insecticide sprays over 7 days 0 0.0 (0.0, 97.5) 4 2.0 (0.5, 5.0) 4 2.0 (0.5, 4.9)
Traditional repellents over 7 days 0 0.0 (0.0, 97.5) 20 9.9 (6.1, 14.8) 20 9.8 (6.1, 14.7)
Residual spray on interior walls in past 
12 months
0 0.0 (0.0, 97.5) 6 3.0 (1.1, 6.3) 6 2.9 (1.1, 6.3)
Niakhar (Senegal) 6 months–4 years Mosquito net in the night before visit 5 100 (47.8, 100) 323 80.0 (75.7, 83.7) 328 80.2 (76.0, 83.9)
Mosquito coils over 7 days 0 0.0 (0.0, 52.2) 11 2.7 (1.4, 4.8) 11 2.7 (1.4, 4.8)
Insecticide sprays over 7 days 0 0.0 (0.0, 52.2) 1 0.2 (0.0, 1.4) 1 0.2 (0.0, 1.4)
Commercial repellents over 7 days 0 0.0 (0.0, 52.2) 3 0.7 (0.2, 2.2) 3 0.7 (0.2, 2.1)
Traditional repellents over 7 days 1 20.0 (0.5, 71.6) 156 38.6 (33.8, 43.6) 157 38.4 (33.6, 43.3)
Residual spray on interior walls in past 
12 months
0 0.0 (0.0, 52.2) 46 11.4 (8.5, 14.9) 46 11.2 (8.4, 14.7)
5–9 years Mosquito net in the night before visit 3 100 (29.2, 100) 139 70.9 (64.0, 77.2) 142 71.4 (64.5, 77.5)
Mosquito coils over 7 days 0 0.0 (0.0, 70.8) 3 1.5 (0.3, 4.4) 3 1.5 (0.3, 4.3)
Insecticide sprays over 7 days 0 0.0 (0.0, 70.8) 1 0.5 (0.0, 2.8) 1 0.5 (0.0, 2.8)
Commercial repellents over 7 days 0 0.0 (0.0, 70.8) 3 1.5 (0.3, 4.4) 3 1.5 (0.3, 4.3)
Traditional repellents over 7 days 2 66.7 (9.4, 99.2) 68 34.7 (28.1, 41.8) 70 35.2 (28.6, 42.2)
Residual spray on interior walls in past 
12 months
0 0.0 (0.0, 70.8) 20 10.2 (6.3, 15.3) 20 10.1 (6.2, 15.1)
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net the night before the visit. In Keur Socé,  ≥99.2% of 
bed nets were new and impregnated, but ≥41.2% of them 
were also pierced/torn. In Niakhar, ≤18.3% of bed nets 
were new and impregnated, and  ≥43.0% of them were 
pierced/torn. In Burkina Faso, no differences in parasite 
density were observed between children who slept or did 
not sleep under a bed net the night before the visit.
In Burkina Faso, the secondmost common malaria con-
trol measure was the use of mosquito coils, with a larger 
extent in Nouna (8.4% of children) compared to Saponé 
(0.8% of children). In Senegal, the secondmost common 
malaria control measure was the use of traditional repel-
lents, which were not used in Burkina Faso, and the high-
est number of children using traditional repellents was 
registered in Niakhar (37.3% of children).
Exploratory analyses in Burkina Faso suggested that the 
use of any malaria treatment or other medication in the 
past 14 days at both the Nouna and Saponé sites, and the 
use of insecticide sprays at the Nouna site had a potential 
impact on the occurrence of P. falciparum parasitaemia 
(Table  4). Concerning the other factors, rural vs urban 
localization, natural vs cement floor, open vs closed drink-
ing water source, and availability of electricity in the house 
in Nouna, and age and iron vs grass/palm roof in Saponé 
were also shown to have a potential impact on the occur-
rence of P. falciparum parasitaemia (Table 4). In the Sen-
egalese centres, the 95% of all unadjusted ORs included 
the value ‘1’ for the assessed malaria control measures and 
risk factors due to the low number of infected children.
Discussion
Although efforts to control malaria infections have 
expanded considerably over the last years, this disease 
remains a major cause of morbidity and mortality in 
many sub-Saharan Western African countries [1, 20]. 
In this study, a much higher PP of P. falciparum was 
observed during the peak of malaria transmission in the 
two centres in Burkina Faso, where malaria endemicity 
is moderate to high, than in the two Senegalese centres, 
where malaria endemicity is low. A lower proportion of 
children with gametocytes, who constitute a parasite 
reservoir responsible for malaria transmission, was also 
observed in Senegal [21].
In Senegal, the prevalence of P. falciparum ranged 
between 0.5 and 1.5% across both age groups, and was 
the lowest at the Keur Socé site. The low prevalence 
observed in Keur Socé was in line with previous studies 
conducted in 2010 in the same area in children younger 
than 10 years (0.3% [95% CI 0.06–0.8]) [18], and in chil-
dren younger than 5 years (1.5% [95% CI 0.7–2.6]) [22]. 
In Burkina Faso, 41.9–75.4% of children across both 
age groups and both sites were infected with P. falcipa-
rum. These results were in line with a previous study 
suggesting that the Saponé district is a stable malaria 
transmission area, where the malaria burden remained 
significant despite the introduction of effective medi-
cations and control measures [23]. However, these 
findings did not confirm the decline in malaria trans-
mission previously observed in children and adults in 
the region of Nouna, where PP over the rainy season 
decreased from 78.9 in 2000 to 58.4% in 2009, 55.9% 
in 2010 and 49.3% in 2011 [15]. This discrepancy may 
be explained by between-study differences in terms of 
recruitment period, as participants were enrolled in 
October in the previous study and mainly in November 
in this study, and age, as this study was limited to chil-
dren and the other study recruited participants from all 
age groups.
Table 4 Effect of malaria control measures and other factors on the proportion of occurrence of Plasmodium falciparum 
parasitaemia for the two sites in Burkina Faso
OR odds ratio, 95% CI 95% confidence interval
Site Characteristic Category Unadjusted OR (95% CI)
Nouna Malaria treatment in past 14 days Yes vs no 0.323 (0.215, 0.484)
Other medication in the past 14 days Yes vs no 0.563 (0.403, 0.788)
Use of insecticide sprays over 7 days Yes vs missing/no 0.456 (0.225, 0.924)
Age Continuous 1.159 (1.086, 1.236)
Localization Rural vs urban area 2.635 (1.876, 3.701)
Type of location Town vs countryside 0.386 (0.275, 0.542)
Main house construction material: floor Natural vs cement 1.666 (1.191, 2.329)
Main source of drinking water Open vs closed 0.712 (0.510, 0.993)
Presence of electricity Yes vs no 0.401 (0.274, 0.588)
Saponé Malaria treatment in past 14 days Yes vs no 0.143 (0.066, 0.308)
Other medication in the past 14 days Yes vs no 0.300 (0.171, 0.529)
Age Continuous 1.329 (1.242, 1.423)
Main house construction material: roof Iron sheet vs grass/palm 0.631 (0.440, 0.906)
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In this study, the prevalence of P. falciparum was 
lower in infants than in older children, which is in line 
with previous observations [20]. Potential explanations 
for the low prevalence in infants include the protection 
by maternal antibodies, and the fact that infants are less 
attractive to mosquitoes [20, 24, 25] and spend less time 
outdoors after sunset.
Infections with other Plasmodium species were scarce, 
with no infection with P. vivax and only a few cases with 
P. malariae and P. ovale, which is in line with other stud-
ies in Burkina Faso [15, 26], and with the World Malaria 
Report of WHO [2].
In Burkina Faso, malaria control policies include free 
distribution of ITNs, intermittent preventive treat-
ment for pregnant women, treatment of malaria cases 
with ACT, and seasonal malaria chemoprevention [27]. 
In Senegal, malaria control measures recommended by 
WHO, including clinical management of malaria cases 
using RDTs and ACT, universal coverage of LLINs, IRS 
and intermittent preventive treatment, have been imple-
mented since 2005, resulting in a decreased malaria bur-
den [16]. These results suggest that most recommended 
malaria control measures were actually used at the study 
site level, except the distribution of ITNs which were not 
free of charge in Nouna and not included in the poli-
cies in Saponé, and the distribution of LLINs which was 
limited to children younger than 5 years and pregnant 
women in Niakhar. The only recommended malaria con-
trol measures evaluated at individual level were the use 
of mosquito bed nets and IRS. Mosquito nets were fre-
quently used in Burkina Faso (88.6–97.0%) and Senegal 
(64.7–80.2%), and the majority were new and impreg-
nated. In Burkina Faso, PP was higher than expected 
given the strong bed net coverage and the national rec-
ommendations for usage of malaria treatment. The simi-
lar proportion of infected and uninfected children who 
slept under a bed net the night before the visit and the 
absence of observed differences in terms of parasite den-
sity, were other unexpected findings. However, since the 
vast majority of children slept under a bed net, the power 
to detect a significant difference was low. Moreover, the 
proportion of children sleeping under a bed net and the 
number of new and impregnated bed nets might have 
been overestimated because bed nets were not inspected 
and their presence was not confirmed by study staff. Sim-
ilar results were obtained in a previous study showing no 
effect of the ITN campaign in 2010 on the proportion 
of young children with P. falciparum parasitaemia after 
the rainy season in the Nouna area [28]. In Senegal, the 
low use of IRS was unexpected since it is recommended 
by the national guidelines. Besides the recommended 
control measures, the use of additional malaria control 
measures was also evaluated. In both countries, only a 
small number of children used mosquito coils or insecti-
cide sprays. Traditional repellents (plant-based methods 
or petroleum oils [29]) were the secondmost common 
malaria control measure in Senegal, but these were not 
used in Burkina Faso.
In Burkina Faso, exploratory analyses suggested that 
malaria control measures having an impact on the P. 
falciparum infection status included the use of malaria 
treatment or other medications in the past 14  days and 
the use of insecticide sprays. Other factors influencing 
malaria occurrence included age, the main house con-
struction material (natural floor and grass/palm roof), 
lack of electricity in the house, and rural residence.
The main strengths of this cross-sectional study are 
the indicators of the high quality of data collection, as 
no child was excluded from the total cohort, and the low 
number of protocol deviations, which were all consid-
ered as minor. The limitations included the low number 
of sites per country and the small sample size per site. 
Moreover, the results from a single cross-sectional survey 
should be interpreted cautiously because they do not take 
annual fluctuations of malaria transmission into account 
and they may not accurately represent the average MTI 
in endemic areas. The PP in Saponé could have been 
slightly underestimated since the peak in malaria trans-
mission occurs in September in this area [16]. Another 
limitation was the potential underestimation of the PP 
when microscopy is used alone, especially in Senegal 
where malaria transmission is reduced and individuals 
may carry sub-microscopic malaria parasites [18].
The estimation of PP could be improved if microscopy 
results were confirmed by molecular detection tech-
niques. Polymerase chain reactions (PCR) have a higher 
sensitivity than microscopy, but this technique is not fre-
quently used in routine clinical practice due to its high 
cost. An estimate of PCR prevalence could be obtained 
by using a tool that has been developed to assess the rela-
tionship between microscopy and PCR measures [30]. 
Finally, the potential differences observed in this study 
and the evaluation of the impact of the various factors on 
the P. falciparum infection status were based on explora-
tory analyses, which should be interpreted with caution 
because there was no adjustment for multiplicity and 
no analysis on multi-collinearity was done before the 
regression.
Conclusions
This study showed that the prevalence of P. falciparum 
was much higher in the two sites in Burkina Faso with 
moderate-to-high malaria endemicity compared with 
the two sites in Senegal with low malaria endemicity. 
Mosquito nets were frequently used in both countries, 
but additional malaria control measures evaluated at 
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individual level were uncommon. Exploratory analy-
ses suggested that control measures having an impact 
on the P. falciparum infection status included the use 
of malaria treatment, other medications and insecticide 
sprays. In the centres with moderate-to-high malaria 
endemicity, age, main house construction material and 
lack of electricity in the house were also associated with 
an increased malaria occurrence. The high PP observed 
in the two sites in Burkina Faso suggests that new malaria 
control measures are needed in these areas.
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